Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase EARLY_PHASE1 1

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Smoldering Multiple Myeloma 1Leukemia, Myeloid, Acute 1Breast Neoplasms 1

Interventions

pembrolizumab 1251Specimen Handling 867Carboplatin 816Magnetic Resonance Spectroscopy 803Cyclophosphamide 794Cisplatin 715Nivolumab 646Paclitaxel 623Radiotherapy 564Gemcitabine 562Biopsy 529Bevacizumab 468Dexamethasone 433fludarabine 404Docetaxel 370venetoclax 365Oxaliplatin 362Fluorouracil 352Capecitabine 350atezolizumab 341Rituximab 326durvalumab 326Doxorubicin 313Radiosurgery 305Pemetrexed 302Drug Therapy 294Standard of Care 292Ipilimumab 289Etoposide 279Radiation 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Immunotherapy, Active × 1 year × Clear all
NCT07551037 2026-05-01

AML

Fujian Medical University Union Hospital

Phase 1 Recruiting
90 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06324240 2026-01-26

Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

Emory University

Phase 1 Recruiting
18 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03631043 2025-12-19

Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Completed
30 enrolled
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡